- Home
- AVTX vs GDO Comparison
AVTX vs GDO Comparison
Compare AVTX & GDO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AVTX | GDO |
|---|---|---|
| Founded | 2011 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 982.5M | 80.2M |
| IPO Year | 2015 | 2009 |
Fundamental Metrics
Financial Performance| Metric | AVTX | GDO |
|---|---|---|
| Price | $16.05 | $9.76 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $40.57 | N/A |
| AVG Volume (30 Days) | ★ 870.6K | 38.8K |
| Earning Date | 05-08-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 72.07 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $27,813,137.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 2312.27 | N/A |
| 52 Week Low | $9.54 | $9.90 |
| 52 Week High | $24.27 | $12.15 |
Technical Indicators
Market Signals| Indicator | AVTX | GDO |
|---|---|---|
| Relative Strength Index (RSI) | 32.92 | 11.16 |
| Support Level | $15.24 | N/A |
| Resistance Level | $16.80 | $10.86 |
| Average True Range (ATR) | 1.04 | 0.06 |
| MACD | -0.45 | -0.03 |
| Stochastic Oscillator | 12.25 | 0.00 |
Price Performance
Historical ComparisonAbout AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.
About GDO Western Asset Global Corporate Defined Opportunity Fund Inc.
Western Asset Global Corp Defined Opp is a closed-end management investment company with a primary investment objective to provide current income. Its secondary objective is to seek capital appreciation. The Fund invests in the United States and foreign corporate fixed-income securities of varying maturities.